The global veterinary endocrinology market is projected to grow at a CAGR of 6.6% between 2025 and 2033, driven by rising awareness of hormonal disorders in companion and livestock animals, increasing veterinary diagnostic capabilities, and expanding availability of treatment options. Endocrine disorders such as diabetes, thyroid dysfunctions, and adrenal abnormalities are increasingly diagnosed among pets and farm animals due to improved routine screening, better owner compliance, and the rising standard of veterinary care. The shift toward preventive animal healthcare, pet humanization, and tailored therapeutic protocols are accelerating demand for both pharmacological and non-pharmacological treatment options in veterinary endocrinology.
The global pharmaceutical gelatin market is growing at a CAGR of 5.6% from 2024 to 2033. Pharmaceutical gelatin, a purified protein derived from collagen, is extensively used across the pharmaceutical industry for applications such as capsule manufacturing, wound dressings, plasma expanders, suppositories, and vaccine stabilizers. It serves as a critical excipient due to its unique functional properties including thermo-reversibility, biocompatibility, and high film-forming capability.
The onychomycosis treatment market is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.0% from 2025 to 2033, driven by the rising incidence of fungal nail infections, growing aging population, increasing diabetes prevalence, and expanding demand for aesthetic foot care solutions. Onychomycosis, a fungal infection affecting toenails and fingernails, is increasingly being recognized as a medical and cosmetic concern, resulting in heightened demand for timely diagnosis and effective treatment interventions.
The epilepsy treatment drugs market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% from 2025 to 2033, driven by the increasing global prevalence of epilepsy, continuous development of newer antiepileptic drugs (AEDs), and improvements in neurological diagnostics. Epilepsy affects over 50 million people globally, and treatment typically involves long-term use of AEDs. The rising demand for more effective and better-tolerated therapies has propelled research in both novel formulations and precision medicine approaches.
The connective tissue disease treatment market is projected to grow at a CAGR of 5.8% during the forecast period 2025 to 2033, driven by the increasing prevalence of autoimmune and inflammatory connective tissue disorders and rising demand for effective long-term therapies. Treatments for connective tissue diseases, which include conditions like systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis, require immunomodulation, anti-inflammatory management, and symptomatic relief. Medications commonly used in this market improve mobility, reduce pain, and prevent long-term organ damage.
The physiotherapy equipment market is projected to grow at a CAGR of 6.6% during the forecast period 2025 to 2033. The market is driven by the rising prevalence of chronic musculoskeletal and neurological conditions, increased demand for rehabilitation therapies, and growing awareness of non-invasive treatment options. Physiotherapy equipment plays a vital role in restoring, maintaining, and enhancing physical function and mobility through various modalities such as electrotherapy, ultrasound, heat therapy, and exercise-based rehabilitation.
The Measles, Mumps, Rubella (MMR) vaccine market refers to the global industry focused on the development, production, and distribution of combination vaccines that provide immunization against three highly contagious viral diseases - measles, mumps, and rubella. These vaccines are typically administered to infants and young children as part of national immunization programs and are recommended by global health authorities for their efficacy in preventing outbreaks, reducing mortality rates, and ensuring herd immunity. The market includes monovalent and trivalent formulations, multivalent vaccines combined with other antigens (such as varicella), and increasingly includes regional and travel-based immunization solutions.
The pharmaceutical cartridges market involves the production and distribution of specially designed cartridges used in the packaging and delivery of pharmaceutical products. These cartridges are primarily used in pen injectors and other drug delivery systems for the administration of precise doses of medication, particularly for chronic conditions such as diabetes, rheumatoid arthritis, and growth hormone deficiencies. The cartridges are made from materials like glass or plastic that meet stringent medical-grade standards to ensure safety, stability, and compatibility with various drugs. The pharmaceutical cartridges market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% over the forecast period.
Hazardous waste management refers to the systematic control of the collection, treatment, and disposal of waste materials that pose a substantial or potential threat to public health or the environment. This includes chemical, biological, and physical waste products that require specialized protocols to prevent pollution and ensure safety in handling, transportation, and disposal. The process encompasses a variety of strategies, such as recycling, incineration, landfilling, and chemical treatment, tailored to mitigate the harmful effects of different types of hazardous substances commonly generated by industries, healthcare facilities, laboratories, and construction sites. Projected to grow at a compound annual growth rate (CAGR) of 5.30% over the forecast period.
The Critical Limb Ischemia (CLI) treatment market involves medical and surgical interventions used to restore blood flow to limbs that have severe arterial blockages, typically in the legs. CLI is a serious condition characterized by chronic pain, sores, and ulcers due to inadequate blood flow, often leading to limb amputation if untreated. Treatments for this condition range from pharmacological therapies aimed at symptom management and improving blood flow, to invasive procedures like angioplasty, stenting, and surgical bypass, as well as advanced therapies like stem cell and gene therapies aimed at vascular regeneration. The Critical Limb Ischemia treatment market is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2033.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.